Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harvard Bioscience reports strong Q4 earnings, eyes China growth

Harvard Bioscience delivered solid financial performance in Q4 2022 with revenue growth and strong margins.
The company faces challenges in supply chain issues and debt reduction but is focused on growth opportunities.
Strategic plans for new product development and improving gross margins are key priorities for future success.

Harvard Bioscience reports strong Q1 earnings, eyes growth opportunities

Harvard Bioscience delivered solid Q1 2023 results with revenue growth, improved margins, and enhanced profitability. While facing challenges in sales organization and market shifts, the company is strategically positioned to capitalize on opportunities for growth through new product offerings and operational efficiencies.

Harvard Bioscience reports mixed Q2 results, eyes growth opportunities

Harvard Bioscience's Q2 2023 performance showed slight revenue decline but notable improvements in margins and profitability.
The company's strengths include new product launches, positive financial metrics, and a promising revenue guidance for 2023.
Challenges include managing discontinued products impact, sales force effectiveness, and profitability.
Opportunities exist in leveraging new products, addressing challenges, and optimizing financial performance drivers.

Harvard Bioscience reports improved margins and profitability in Q3

Harvard Bioscience (HBIO) showed mixed performance in Q3 2023 with revenue decline but improved margins and profitability. The company aims to sustain growth through new product launches and service expansion while managing debt effectively.

Harvard Bioscience reports Q4 results, eyes growth through new products

Harvard Bioscience reported mixed Q4 2023 results with revenue decline in some regions.
The company aims for long-term growth through new products and market expansion.
Challenges include revenue decline in certain regions and maintaining/improving margins.
Opportunities lie in new product launches, partnerships, and market expansion strategies.

Harvard Bioscience faces Q1 revenue dip, eyes second-half turnaround

Harvard Bioscience navigated a tough Q1 marked by revenue declines in key regions and operational challenges. However, the company's focus on new product launches and efficiency in maintaining a strong gross margin are positive indicators. Looking ahead, Harvard Bioscience anticipates a turnaround in the second half of the year with improved margins and overall performance.

Harvard Bioscience reports Q3 revenue decline, eyes growth opportunities

Harvard Bioscience faced revenue decline in Q3 due to China and Asia Pacific weakness but expects stabilization and growth.
Operational improvements and cost reductions are enhancing efficiency and profitability.
New product launches and focus on high-growth areas position the company for incremental growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harvard Bioscience's (HBIO) CEO Jim Green on Q2 2019 Results - Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) CEO Jeffrey Duchemin on Q1 2019 Results - Earnings Call Transcript

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -33.33% and -0.95%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Lags Q1 Earnings and Revenue Estimates

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harvard Bioscience (HBIO) Q1 Earnings Preview: What's in the Cards?

News for Harvard Bioscience Stock (HBIO)